-
Journal of Wound Care Mar 2023The aim of this study was to examine the in vivo wound healing potential of Hedge (endemic to Turkey) on excision and incision wound models in diabetic rats. Male...
The aim of this study was to examine the in vivo wound healing potential of Hedge (endemic to Turkey) on excision and incision wound models in diabetic rats. Male Wistar albino rats, 3-4 months old and weighing 180-240g were used. The animals were randomly divided into five groups including Control, Vehicle and Fito reference, and two different concentrations (0.5% and 1% weight/weight (w/w)) of ethanol extract of were investigated in both wound models on streptozocin-induced diabetic rats using macroscopic, biomechanical, biochemical, histopathological, genotoxic and gene expression methods over both seven and 14 days. Fito cream (Tripharma Drug Industry and Trade Inc., Turkey) was used as the reference drug. A total of 60 rats were used in this study. ointments at 0.5% and 1% (w/w) concentrations and Fito cream showed 99.3%, 99.4% and 99.1% contraction for excision wounds, and 99.9%, 97.0% and 99% contraction for incision wounds, respectively. In ointments and Fito cream groups, re-epithelialisation increased dramatically by both day 7 and day 14 (p<0.05). By day 14, low hydroxyproline and malondialdehyde (MDA) levels, and high glutathione (GSH) levels were observed in the ointment groups. After two application periods, damaged cell percent and genetic damage index values and micronucleus frequency of ointment treatment groups were lower than Control and Vehicle groups (p<0.001). A growth factor expression reached a high level by day 7 in the Control group; in -treated groups it was decreased. The study showed that application of ointments ameliorated the healing process in diabetic rats with excisional and incisional wounds and may serve as a potent healing agent.
Topics: Male; Animals; Rats; Streptozocin; Diabetes Mellitus, Experimental; Plant Extracts; Ointments; Salvia; Rats, Wistar; Wound Healing; Ethanol; Surgical Wound
PubMed: 36930535
DOI: 10.12968/jowc.2023.32.Sup3a.i -
CMAJ Open 2021Topical nitroglycerin (TNG) ointment has been used for almost 3 decades to treat neonatal peripheral tissue ischemia, but this product is now no longer being produced by...
BACKGROUND
Topical nitroglycerin (TNG) ointment has been used for almost 3 decades to treat neonatal peripheral tissue ischemia, but this product is now no longer being produced by its Canadian manufacturer. Our aim was to investigate the efficacy and safety of TNG products in newborns in neonatal intensive care units.
METHODS
In this systematic review we searched Embase, CINAHL, MEDLINE, PubMed and Web of Science from inception to April 2020 for studies on the use of TNG products (TNG ointment, TNG spray, glyceryl trinitrate [GTN] patch) for the treatment of neonatal tissue ischemia. We did not apply language or study design limitations. Animal studies and duplicate records were excluded. Two reviewers screened and extracted data. The Tool for Evaluating the Methodological Quality of Case Reports and Case Series was used to assess the risk of bias of individual studies.
RESULTS
We included 23 articles (20 case reports, 2 case series and 1 retrospective audit) describing the use of TNG ointment, TNG spray or GTN patch in the treatment of 39 tissue ischemia events in 37 newborns. Twenty-three (62.2%), 12 (32.4%), 1 (2.7%) and 1 (2.7%) infants received TNG ointment, GTN patch, both TNG ointment and GTN patch, and TNG spray, respectively. Nineteen (76.0%) and 7 (53.8%) injuries treated with TNG ointment and GTN patch showed complete recovery, respectively. Two (16.7%) infants treated with GTN patch experienced adverse events (i.e., methemoglobinemia) requiring treatment discontinuation.
INTERPRETATION
TNG ointment presents a safe therapeutic modality for salvage therapy of neonatal tissue ischemia. Engagement of stakeholders is essential to address its recent commercial inaccessibility in Canada.
Topics: Administration, Cutaneous; Catheterization, Peripheral; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Ischemia; Nitroglycerin; Ointments; Salvage Therapy; Vasodilator Agents
PubMed: 33731426
DOI: 10.9778/cmajo.20200129 -
BioMed Research International 2021Antiseptic wound ointments are widely used to treat dermal wounds that are microbially contaminated. Polygalacturonic acid (PG)+caprylic acid (CAP) is a novel...
Antiseptic wound ointments are widely used to treat dermal wounds that are microbially contaminated. Polygalacturonic acid (PG)+caprylic acid (CAP) is a novel combination that has been shown to eradicate biofilms. We developed a novel PG+CAP ointment and compared the biofilm eradication capability and cytotoxicity of PG+CAP with that of commercially available antiseptic wound ointments. We used a well-established biofilm model to quantitatively assess the eradication of organisms following exposure to the wound ointments for 2 hours. PG+CAP ointment completely eradicated , multidrug-resistant , and methicillin-resistant biofilms, whereas MediHoney, polyhexamethylene biguanide (PHMB), and benzalkonium chloride (BZK) ointments failed to eradicate all biofilms within 2 hours. We assessed cytotoxicity by exposing L-929 fibroblasts to extracts of each ointment; Trypan blue exclusion was used to assess cell viability, and Alamar blue conversion was used to assess metabolic function. After exposure to PG+CAP and MediHoney, fibroblast viability was 96.23% and 95.23%, respectively (Trypan blue), and was comparable to untreated cells (98.77%). PHMB and BZK showed reduced viability (83.25% and 77.83%, respectively, < 0.05). Metabolic activity results followed a similar pattern. Cytotoxicity of PG+CAP ointment towards erythrocytes was comparable to saline. PG+CAP ointment seems to be safe and can rapidly eradicate microbial biofilm; thus, PG+CAP ointment merits further in vivo testing as a potential antimicrobial wound ointment.
Topics: Animals; Anti-Infective Agents, Local; Biofilms; Candida albicans; Caprylates; Cell Line; Methicillin-Resistant Staphylococcus aureus; Mice; Ointments; Pectins; Pseudomonas aeruginosa
PubMed: 33708989
DOI: 10.1155/2021/2710484 -
Acta Dermato-venereologica Feb 2021Gentamicin ointment has potential in the treatment of Nagashima-type palmoplantar keratosis. However, there is a lack of reliable study data. The aim of this study was... (Randomized Controlled Trial)
Randomized Controlled Trial
Gentamicin ointment has potential in the treatment of Nagashima-type palmoplantar keratosis. However, there is a lack of reliable study data. The aim of this study was to perform a prospective, randomized, double-blinded, contralateral, vehicle-controlled clinical trial. A total of 20 subjects diagnosed with Nagashima-type palmoplantar keratosis by genetic test, who carried nonsense mutations, enrolled in the 30-day study. Gentamicin ointment was applied to the hand and foot on one side of the body, and vehicle ointment was applied to the hand and foot on the other side. The choice of hand and foot in each subject was randomly allocated. The severity of the patient's skin lesions and quality of life were assessed by a blinded evaluator, using the Dermatology Life Quality Index, visual analogue scale scores and digital photography. Gentamicin ointment treatment resulted in a significant improvement in symptoms of hyperkeratosis and foul smell compared with vehicle. No difference was found in the effect on erythema between gentamicin and vehicle. In conclusion, gentamicin ointment demonstrated positive responses and good tolerance in treating Nagashima-type palmoplantar keratosis caused by nonsense mutations.
Topics: Double-Blind Method; Gentamicins; Humans; Keratoderma, Palmoplantar; Ointments; Prospective Studies; Quality of Life; Serpins
PubMed: 33554268
DOI: 10.2340/00015555-3760 -
Experimental Dermatology May 2021This study aimed to investigate the molecular effects of radiation and subsequent aftercare treatment with dexpanthenol-containing ointment and liquid on established...
Molecular effects of photon irradiation and subsequent aftercare treatment with dexpanthenol-containing ointment or liquid in 3D models of human skin and non-keratinized oral mucosa.
This study aimed to investigate the molecular effects of radiation and subsequent aftercare treatment with dexpanthenol-containing ointment and liquid on established full-thickness 3D skin models depicting acute radiodermatitis and mucositis. To mimic radiomucositis and radiodermatitis, non-keratinized mucous membrane and normal human skin models were irradiated with 5 Gray. Afterwards, models were treated topically every second day with dexpanthenol-containing ointment or liquid in comparison with placebo and untreated controls. On day 7 after irradiation, histological examination showed impairments in irradiated models. In contrast, models treated with dexpanthenol-containing ointment or liquid showed a completely restored epidermal part. While gene expression profiling revealed an induction of genes related to a pro-inflammatory milieu, oxidative stress and an impaired epidermal differentiation after irradiation of the models, aftercare treatment with dexpanthenol-containing ointment or liquid revealed anti-oxidative and anti-inflammatory effects and had a positive effect on epidermal differentiation and structures important for physical and antimicrobial barrier function. Our findings confirm the potential of our established models as in vitro tools for the replacement of pharmacological in vivo studies regarding radiation-induced skin injuries and give indications of the positive effects of dexpanthenol-containing externals after radiation treatments as part of supportive tumor treatment.
Topics: Administration, Topical; Aftercare; Dermatologic Agents; Epidermis; Humans; Keratinocytes; Mouth Mucosa; Ointments; Pantothenic Acid; Wound Healing
PubMed: 33403711
DOI: 10.1111/exd.14266 -
Clinical and Experimental Dermatology Jul 2022Emollients are used as maintenance therapy for all severities of eczema but there is a lack of head-to-head comparisons of effectiveness and acceptability.
BACKGROUND
Emollients are used as maintenance therapy for all severities of eczema but there is a lack of head-to-head comparisons of effectiveness and acceptability.
AIM
To determine the validity of a self-report questionnaire designed to assess user satisfaction with a given emollient and to report the findings.
METHODS
Data were analysed from the Choice of Moisturiser for Eczema Treatment trial, which compared four emollient types (Aveeno lotion, Diprobase cream, Doublebase gel and Hydromol ointment) in children aged < 5 years with clinically diagnosed eczema. An emollient satisfaction questionnaire was completed after 12 weeks. Responses for individual items were scored from 0 to 4. Total scores ranged from 0 to 28 (low to high satisfaction). Completion rates and distributions of responses for individual items and total scores, categorized by emollient type, were assessed, and two hypotheses were tested to determine the questionnaire's construct validity.
RESULTS
Data from 77.2% (152 of 197) of participants were analysed. One item was rejected because of a high rate (44.7%) of 'don't know' responses, leaving seven items with high completion rates (98.7%) and weak evidence of floor or ceiling effects. A positive association was observed between total score and overall emollient satisfaction (Spearman correlation 0.78; P < 0.001). Total scores were highest (mean ± SD 23.5 ± 3.9) in the lotion group and lowest (18.4 ± 4.6) in the ointment group.
CONCLUSION
The emollient satisfaction questionnaire appears to have good validity. Further work is required to validate the questionnaire in other settings and to assess its reliability.
Topics: Child, Preschool; Clinical Trials as Topic; Eczema; Emollients; Humans; Ointments; Personal Satisfaction; Reproducibility of Results; Surveys and Questionnaires; Treatment Outcome
PubMed: 35315540
DOI: 10.1111/ced.15189 -
Combinatorial Chemistry & High... 2021Shoulder-hand syndrome (SHS) refers to a syndrome causing sudden edema, shoulder pain and limited hand function. Qingpeng ointment, a kind of Tibetan medicine, can... (Randomized Controlled Trial)
Randomized Controlled Trial
BACKGROUND
Shoulder-hand syndrome (SHS) refers to a syndrome causing sudden edema, shoulder pain and limited hand function. Qingpeng ointment, a kind of Tibetan medicine, can reduce swelling, relieve pain, tonify stagnation and clear the meridians, which is consistent with the pathological mechanism of SHS after stroke. Therefore, if clinical trials can be used to explore the effectiveness of Qingpeng ointment for the treatment of poststroke SHS and promote its application in clinical medicine, it may prove the specific significance for the treatment of poststroke SHS poststroke SHS.
OBJECTIVE
The aim of the study was to investigate the clinical efficacy and safety of Qingpeng ointment in the treatment of poststroke SHS and to provide an objective basis for a better therapeutic treatment for poststroke SHS.
METHODS
A prospective, randomized, controlled study was conducted. This study recruited 120 patients with poststroke SHS who met the inclusion criteria. They were randomized into the treatment group and the control group, with 60 patients allocated to each group. The treatment group received routine medical treatment and rehabilitative care after using the Qingpeng ointment, while the patients in the control group received only routine treatment without the ointment. All patients received clinical assessment with the Visual Analogue Scale (VAS), measurement of the range of motion (ROM) of the upper-limb joints, the Fugl-Meyer Assessment of Upper Extremity (FMA-U) and the Modified Barthel Index Score (MBI) before and after the whole treatment.
RESULTS
After 4 weeks of treatment, the VAS scores of both the groups decreased significantly (P <0.05), and the difference between the two groups was statistically significant (P < 0.05). No statistical significance was observed for the difference between the treatment group and control group in terms of the FMA-U and MBI scores and the forward bend, backward, outstretch, external rotation and pronation angles after treatment. The increases in the values of VAS, FMA-M and MBI in the treatment group were greater than those in the control group, and the difference was statistically significant (P < 0.05). The increases in the values of the forward bend, outreach and external rotation angles in the treatment group were greater than those in the control group, and the difference was statistically significant (P < 0.05).
CONCLUSION
The treatment group showed better results than the control group in terms of the relief of pain symptoms, the improvement of motor function and the improvement of the activities of daily living for patients with shoulder-hand syndrome after cerebral hemorrhage. Qingpeng ointment was found to be effective and safe for treating poststroke SHS.
Topics: Cerebral Hemorrhage; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Ointments; Prospective Studies; Reflex Sympathetic Dystrophy
PubMed: 33308122
DOI: 10.2174/1386207323666201211093227 -
Drug and Chemical Toxicology Nov 2023The aim of the study was to assess the toxicity profile of extract and evaluate its wound healing activity.
AIM
The aim of the study was to assess the toxicity profile of extract and evaluate its wound healing activity.
METHODS
wound healing activity of extract (5% and 10%) was performed using Clonogenic and Scratch assays. The toxicity profile of extract ointment was evaluated on animals using acute toxicity and dermal toxicity tests. wound healing activity of extract ointment (5% and 10%) was used to determine tensile strength in the incision wound healing model.
RESULTS
Results exhibited that the extract was safe up to 2000 mg/kg per oral dose and non-reactive while applied topically. results showed that extract closed the wound gap created by 97.13% in 48 h. The clonogenic assay revealed that the surviving factor for HaCaT cells and MEF cells was 0.78 and 0.85 after treated with 10% concentrations of . The tensile strength exhibited by 5% and 10% groups was 395.4 g and 558.5 g in comparison to the control group.
CONCLUSION
Thus, extract can be used as an alternative safe drug therapy against topical wounds.
Topics: Rats; Animals; Selaginellaceae; Rats, Wistar; Plant Extracts; Ointments; Wound Healing
PubMed: 35635134
DOI: 10.1080/01480545.2022.2075378 -
International Journal of Biological... Sep 2022Antimicrobial-resistant is a major challenge in to treat infected wounds, and new formulations should be produced. Citral (Citl), chitosan (Chsn), and zinc oxide (ZnO)...
Antimicrobial-resistant is a major challenge in to treat infected wounds, and new formulations should be produced. Citral (Citl), chitosan (Chsn), and zinc oxide (ZnO) nanoparticles may accelerate the wound healing process in terms of their antibacterial properties. This new study aimed to investigate the effects of ointments produced from ZnO/Chsn/Citl nanoparticles (NPs) to treat the infected wounds. Following the preparation of ZnO/Chsn/Citl-NPs, swelling behavior, the release of citral, toxicity, and antibacterial properties were evaluated. Base ointment, mupirocin, and ointments made from Chsn-NPs, Chsn/Citl-NPs, and ZnO/Chsn/Citl-NPs were used to treat the mice. The ointments' effects on wound contraction, total bacterial count, and immunofluorescence staining for TNF-α, TGF-β, and bFGF were tested. The synthesis of ZnO/Chsn/Citl-NPs was validated by XRD, FT-IR, DLS, and TEM findings. In higher dilutions, chitosan/citral and ZnO/Chsn/Citl-NPs indicated better antibacterial activity. Nanoparticles were safe up to concentration of the 0.5 mg/mL. The mice in Chsn/Citl and ZnO/Chsn/Citl-NPs treated groups showed higher (P < 0.05) wound contraction ratio and expressions for bFGF, and lower total bacterial count and expressions for TGF-β and TNF-α compared to control mice. Ointments prepared from ZnO/Chsn/Citl-NPs could compete with the commercial ointment of mupirocin and can be used to treat infected wounds after clinical studies.
Topics: Acyclic Monoterpenes; Animals; Anti-Bacterial Agents; Chitosan; Metal Nanoparticles; Mice; Microbial Sensitivity Tests; Mupirocin; Nanoparticles; Ointments; Spectroscopy, Fourier Transform Infrared; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Wound Healing; Zinc Oxide
PubMed: 35820486
DOI: 10.1016/j.ijbiomac.2022.07.038 -
European Journal of Ophthalmology Jan 2024The purpose of this study was to assess the use of topical tacrolimus ointment in preventing rejection in high-risk corneal grafts, when added to the standard... (Observational Study)
Observational Study
PURPOSE
The purpose of this study was to assess the use of topical tacrolimus ointment in preventing rejection in high-risk corneal grafts, when added to the standard immunosuppressive regimen.
METHODS
We conducted an observational, retrospective study using clinical data of high-risk patients subjected to penetrating keratoplasty, who were treated with topical tacrolimus ointment 0.2 mg/g twice a day plus topical dexamethasone 0.1 mg/ml 6 id and compared it with a similar control group treated with topical dexamethasone 0.1 mg/ml 6 id alone. High-risk status was attributed to patients with previous ipsilateral corneal graft failure, two or more quadrants with corneal neovascularization or an infectious or inflammatory corneal disease.
RESULTS
We analysed 53 patients in the trial group versus 53 patients in the control group, with similar age, baseline diagnosis and risk factors, and median follow-up times of 30 and and 24 months, respectively. Survival analysis showed a higher graft survival rate at all follow-up periods for patients treated with topical tacrolimus ( < 0.01). No adverse reactions were reported.
DISCUSSION
This study shows that topical tacrolimus ointment increases the survival rate of the graft if added to the previous topical steroid regimen in high-risk patients.
CONCLUSION
Topical tacrolimus is safe and effective in prolonging graft survival in high-risk patients.
Topics: Humans; Tacrolimus; Retrospective Studies; Ointments; Graft Rejection; Immunosuppressive Agents; Corneal Transplantation; Keratoplasty, Penetrating; Corneal Diseases; Dexamethasone; Administration, Topical
PubMed: 37128645
DOI: 10.1177/11206721231172236